Anstee QM, et al. - In order to evaluate the ability of noninvasive tests (NITs) to discriminate advanced fibrosis due to nonalcoholic steatohepatitis (NASH), researchers studied screening data from two phase 3 trials of selonsertib. The links between fibrosis stage and NITs, including the NAFLD fibrosis score, Fibrosis-4 index, Enhanced Liver Fibrosis test, and liver stiffness by vibration-controlled transient elastography (LS by VCTE), were examined. Using AUROCs with 5-fold cross-validation repeated 100 times, they assessed the performance of these tests to distinguish advanced fibrosis, either alone or in combinations. Findings revealed that the requirement for liver biopsy to discriminate advanced fibrosis due to NASH, in patients being considered for enrolment into clinical trials, can be attenuated with NITs alone or in combination. Corroboration in a real-world population is needed for the predictive significance of these tests for general screening.